Kasuki Leandro, Wildemberg Luiz Eduardo, Gadelha Mônica R
Neuroendocrinology Research Center/Endocrine Section and Medical School, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Neuroendocrine Section, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.
Eur J Endocrinol. 2018 Mar;178(3):R89-R100. doi: 10.1530/EJE-17-1006. Epub 2018 Jan 16.
Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose.
肢端肥大症若未得到充分治疗，会导致高发病率和死亡率升高。手术是大多数患者的一线治疗方法，因为它是唯一能实现即刻治愈的方法。对于手术无法治愈的患者，目前的治疗基于试错法。大多数患者开始使用第一代生长抑素受体配体（fg-SRL）进行治疗，尽管约25%的患者对这类药物存在耐药性。文献中描述了一些治疗结果的生物标志物，目的是将患者分为不同组，以便采用个性化方法进行个体化治疗。在本综述中，我们将讨论肢端肥大症精准医学治疗的现状以及为此使用个性化医学的未来前景。
